Clinical Evaluation Of The Nano Lv Lead System In Chronic Situation (LENEA)

Clinical Evaluation Of The Nano Lv Lead System In Chronic Situation

Status

Terminated

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01731210

Acronym

LENEA

Enrollment

Registered

2012-11-21

Start date

2012-10-31

Completion date

2013-12-19

Last updated

2018-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

LV Lead, LV Microcable, LV Therapy, LV Treatment

Brief summary

The LENEA study is an international, prospective, open label, non-randomized multicenter clinical research study designed to assess the safety and effectiveness of the NANO LV lead system.

Interventions

DEVICEimplantation of the new LV lead: NANO system.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

NANO LV lead

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Approved indication per ACC/AHA/HRS guidelines for implantation of a CRT-D system for treatment of heart failure or life threatening ventricular tachyarrhythmia(s) * Receiving a new implant OR undergoing an upgrade from an existing ICD or pacemaker implant with no prior implanted LV lead OR undergoing a new LV implant attempt consecutive to a recent LV lead placement failure not related to coronary sinus cannulation failure * Patient receiving the PARADYM RF CRT or PARADYM RF CRT SONR devices * Ability to provide informed consent for study participation and is willing and able to comply with the prescribed follow-up tests and schedule of evaluations

Exclusion criteria

* Ventricular tachyarrhythmia of transient or reversible causes such as acute myocardial infarction, digitalis intoxication, drowning, electrocution, electrolyte imbalance, hypoxia or sepsis, uncorrected at the time of the enrolment; * Incessant Ventricular tachyarrhythmias; * Unstable angina, or acute MI , CABG , or PTCA within the past 4 weeks; * Correctable valvular disease that is the primary cause of heart failure; * Post heart transplant (patients who are waiting for a heart transplant are allowed in the study); * Patient who had previously a permanently implanted LV lead; * Concurrent implant with another pacemaker or ICD (previously implanted pacemaker or ICD devices should be removed prior to implant with the Paradym RF CRT-D or Paradym RF CRT SONR); * Already included in another clinical study that could confound the results of this study; * Life expectancy less than 1 year.

Design outcomes

Primary

Measure	Time frame
Freedom from left ventricular lead related complications through 1 month	1 month

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026